Opaleye Management Inc.'s Form 4 filing
Tracon Pharmaceuticals, Inc. (TCON) · filed Apr 29, 2022
- Accession no.
- 0001493152-22-011655
- Filed
- Apr 29, 2022
- Trade date
- Apr 22, 2022
- Filing delay
- 7 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $14.1K. It was filed 7 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 22, 2022 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +6,100 | $1.98F3 | +$12,078 | 2,926,100 | Indirect | |
| Apr 22, 2022 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +1,000 | $1.98F3 | +$1,980 | 336,114 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The common stock was purchased by the reporting person in open market transactions on the transaction date, with a purchase price of $1.98. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
Referenced by the price of 2 transactions in Table I.